Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Symphogen, a developer of recombinant polyclonal antibodies, has secured approximately $44 million in financing. Existing investors participated in the round, which was led by Essex Woodlands Health Ventures.
Subscribe to our email newsletter
The financing will be used to mature the company’s product pipeline of antibody therapeutics, particularly within the field of oncology.
Kirsten Drejer, CEO of Symphogen, said: “The current funding will support the advancement of our lead oncology program, Sym004, towards early clinical studies as Symphogen continues to build a competitive oncology franchise.
“Coinciding with our strategic decision to focus our internal R&D resources on further maturing our oncology pipeline, Symphogen also plans to broaden its external collaborative activities by engaging in partnership discussions for its anti-RSV and anti-RhD recombinant polyclonal antibody programs.”